According to our latest research study on “Human Leukocyte Antigen (HLA) Testing Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by product and service, technology, and end user,” the human leukocyte antigen (HLA) testing market size is projected to reach US$ 1,155.65 million by 2028 from US$ 697.74 million in 2021; it is estimated to grow at a CAGR of 7.5% from 2022 to 2028. The report highlights trends prevailing in the market and factors governing the growth of the market.
Get Your Free Sample Copy Today | Click Here: https://www.theinsightpartners.com/sample/TIPRE00021578
Human leukocyte antigens (HLAs) are the specialized proteins present on all cell surfaces of the human body, except red blood cells. HLA testing has significant application in organ transplantation, which can be recommended as a part of the treatment of kidney failure, chronic liver cirrhosis, and chronic heart disease, among other medical issues.
The growing prevalence of chronic diseases and organ failure leads to high demand for organ transplant procedures, as well as HLA testing. Before transplantation, HLA testing is performed to check tissue compatibility between patients and donors to avoid graft rejection. In recent years, transplantation has become a successful practice worldwide. According to data published in Global Observatory on Donation and Transplantation (GODT), in 2020, 129,681 organ transplants were recorded in total. Of these, 31.7% were living kidney transplants and 20.40% were living liver transplants. The facts mentioned above boost the demand and availability of human leukocyte antigen (HLA) testing, thus driving the entry of more players into the human leukocyte antigen (HLA) testing market
Increasing Government Funding for Organ Donation Creates Opportunities for Human Leukocyte Antigen (HLA) Testing Market Players
Living organ donations and deceased organ donations (DCD) are the two types of organ donations. The demand for both types of organ donations is rising day by day due to the elevating cases of chronic illnesses. According to the US Human Resource and Service Administration (HRSA), ~21 people die waiting for an organ in the US every day.
More than 107,380 men, women, and children in the country await life-saving organ transplants. Additionally, as per the Ministry of Health and Family Welfare (MoHFW) of the Government of India, annually 500,000 people die because of non-availability of organs, 200,000 people die due to liver disorders, and 50,000 people die because of heart disease. Moreover, 150,000 people await a kidney transplant, but only 5,000 get kidneys for transplantation. These numbers indicate the need for organ donors, which is much greater than the actual number of donations. Similar scenarios have been found in other nations of the world.
Product and Services-Based Insights
The human leukocyte antigen (HLA) testing market, based on product and service type, has been segmented into reagents and consumables, instruments, and software and services. The reagent and consumables segment held the largest share of the market in 2021. However, the instrument segment is expected to register the highest CAGR in the human leukocyte antigen (HLA) testing market during 2022–2028.
Technology-Based Insights
Based on technology, the human leukocyte antigen (HLA) market is segmented into molecular assay technologies and non-molecular assay technologies. In 2021, the molecular assay technologies segment held a larger share of the market, and it is expected to report a higher CAGR of 7.7% during 2022–2028.
End User-Based Insights
Based on end user, the human leukocyte antigen (HLA) market is segmented into independent reference laboratories, hospitals and transplant centers, and others. In 2021, the independent reference laboratories segment held the largest share of the market. Further, the hospitals and transplant centers segment is expected to report the highest CAGR of 7.9% during 2022–2028.
Thermo Fisher Scientific Inc., CareDx, Qiagen, Illumina Inc., Bio-Rad Laboratories, Inc., TBG Diagnostics Limited, F.Hoffmann-La Roche Ltd., Takara Bio Inc., Luminex Corporation, Omixon Inc., The Sequencing Center, Protrans, HistoGenetics LLC., CD Genomics, Qunitara Biosciences, CeGat GmbH, and Creative Biolabs Inc. are among the leading companies operating in human leukocyte antigen (HLA) testing market.
The Report Segments Human Leukocyte Antigen (HLA) Testing Market as Follows:
Based on geography, the human leukocyte antigen (HLA) testing market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and the Rest of APAC), the Middle East & Africa (Saudi Arabia, the UAE, South Africa, and the Rest of MEA), and South & Central America (Brazil, Argentina, and the Rest of SCAM).
About US
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Human Leukocyte Antigen (HLA) Testing, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.
Contact US
Contact Person : Ankit Mathur
Phone : +1-646-491-9876
E-mail : [email protected]